POST-TEST

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Which of the following mutations is most commonly observed in patients with higher-risk myelodysplastic syndromes (MDS)?**
   a. ASXL1
   b. DNMT3A
   c. IDH1
   d. IDH2
   e. TP53

2. **Which of the following mutations best describes the molecular target of the novel agent magrolimab?**
   a. CD47
   b. TIM-3
   c. IDH1
   d. FLT3

3. **Magrolimab inhibits tumor cell activity via which of the following mechanisms?**
   a. Promoting tumor cell phagocytosis
   b. Restoring immune surveillance
   c. Inhibiting PI3K/AKT survival signaling

4. **Which of the following treatments is being evaluated in combination with azacitidine for patients with newly diagnosed higher-risk MDS in the Phase III VERONA study?**
   a. Enasidenib
   b. Gilteritinib
   c. Ivosidenib
   d. Magrolimab
   e. Pevonedistat
   f. Venetoclax

5. **Which of the following cell types is the predominant expresser of the sabatolimab target TIM-3?**
   a. Leukemic stem cells
   b. Hematopoietic stem cells
   c. Tissue-resident stem cells